The Human Effect Matrix looks at human studies to tell you what supplements affect C-Reactive Protein.
Full details on all C-Reactive Protein supplements are available to Examine Plus members.
| Grade | Level of Evidence [show legend] |
|---|---|
|
Robust research conducted with repeated double-blind clinical trials |
|
Multiple studies where at least two are double-blind and placebo controlled |
|
Single double-blind study or multiple cohort studies |
|
Uncontrolled or observational studies only |
|
Level of Evidence
?
The amount of high quality evidence. The more
evidence, the more we can trust the results.
|
Supplement |
Magnitude of effect
?
The direction and size of the supplement's impact on
each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
|
Consistency of research results
?
Scientific research does not always agree. HIGH or
VERY HIGH means that most of the scientific research agrees.
|
Notes |
|---|---|---|---|---|
|
|
- | Very High See all 16 studies |
Although some decreases have been noted, the vast majority of the evidence suggests that there is no significant influence
|
|
|
|
Minor
|
High See all 19 studies |
May decrease C-reactive protein if elevated. Studies are somewhat inconsistent, but an effect in those who will benefit most is likely.
|
|
|
|
Minor
|
High See all 3 studies |
There is a decrease in C-Reactive Protein (inflammatory biomarker) in those with higher baseline inflammation or inflammatory disease conditions, but not in healthy persons.
|
|
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
